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Fas- and tumour necrosis factor (TNF) receptor-mediated apoptosis are known to be two principal apoptotic
mechanisms in humans. Although there are several distinctions between these two systems, in vitro studies have
demonstrated similar hypoxic activation and a functional relationship. Since patients with chronic obstructive
pulmonary disease (COPD) show chronic hypoxaemia and the activation of the TNF-a system, we investigated
whether these pathophysiological changes influence the Fas–Fas ligand system. We measured the circulating
soluble Fas ligand (sFas-L) level, an inducer of apoptosis, and the soluble Fas receptor (sFas) level, an inhibitor of
apoptosis, in 34 COPD patients and 35 age-matched healthy controls. In addition, we investigated the relationships
between the levels of sFas-L or sFas and clinical variables including the TNF-a system; circulating TNF-a and
soluble TNF-receptor (sTNF-Rs: sTNF-R55 and R75) levels, in the COPD patients. Although circulating TNF-a,
sTNF-R55 and R75 levels were significantly higher in the COPD patients than in the healthy controls, serum level
of sFas-L (Fisher’s exact probability test; P=0?26) and plasma level of sFas [COPD patients vs. controls; mean
(SD); 3?74 (0?63) vs. 3?67 (0?48) ng/ml; P=0?89) were not increased in the COPD patients. There was no significant
correlation between the levels of sFas-L or sFas and clinical variables in COPD patients. These results suggest that
the Fas–Fas ligand system does not independently play an important role in the pathophysiology of patients with
COPD.
Key words: chronic obstructive pulmonary disease (COPD); Fas–Fas ligand system; tumour necrosis factor-a
(TNF-a) system; apoptosis; correlation analysis; pathophysiological role.
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Fas is a transmembrane receptor that belongs to the TNF/
nerve growth factor (NGF) receptor family (type I
membrane protein), and is widely expressed on normal
and malignant cells (1–5). Fas can occur as both a cell-
surface (Fas) and a soluble protein (sFas). sFas is generated
by alternative mRNA splicing (6,7). The Fas ligand (Fas-L)
is a membrane-bound cytokine and a member of the TNF
family (type II membrane protein) (1–3,8). Fas-L is
predominantly expressed in activated T cells (9). Fas-L
can be processed to a soluble form (sFas-L) by a
metalloproteinase like TNF (10,11). Sensitive cells that
express Fas undergo apoptosis upon contact with Fas-L orReceived 8 November 1999 and accepted in revised form 16 August
2000. Published online 26 September 2000.
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0954-6111/00/121215+06 $35?00/0agonistic, cross-linking antibodies, indicating that Fas-L is
a death factor and that Fas is its receptor (1–3).
Pathologically, the Fas–Fas ligand system is involved in
eliminating autoreactive immune cells, malignant cells, or
virally infected cells (1–3). However, the roles of this system
remain obscure in other pathophysiological conditions.
TNF-a is a pleiotropic cytokine which can induce a
broad variety of cellular responses in many cell types,
inducing differentiation, proliferation, inflammation and
apoptosis (1–3,12). Like Fas, two kinds of TNF-receptors
(TNF-Rs), TNF-R55 and R75, are implicated in the
triggering of apoptosis upon stimulation by its natural
ligand (1–3). Although the Fas- and TNF receptor-
mediated apoptosis are distinct, in vitro studies have
demonstrated that these two systems share several common
properties and show structural and/or functional associa-
tions (13,14). For instance, hypoxia enhances not only
TNF-a expression but also Fas expression in experimental
cell systems (15–18). TNF has been shown to increase Fas
expression in a number of cell types and to increase Fas-
mediated apoptosis (1–3,5,19,20).# 2000 HARCOURT PUBLISHERS LTD
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understand the pathophysiological roles of the Fas–Fas
ligand system in lung diseases (21–23), very few reports
have been published regarding chronic obstructive pulmon-
ary disease (COPD). Since COPD patients show chronic
hypoxaemia and activation of the TNF-a system (24–26), it
seems therefore of primary importance to investigate
whether the Fas–Fas ligand system is influenced by these
physiological changes in patients with COPD.
In this study, we measured the circulating levels of sFas-
L, sFas, TNF-a, and soluble TNF-receptors (sTNF-Rs;
sTNF-R55 and R75) in 34 clinically stable COPD patients
and 35 age-matched healthy controls. We also investigated
the relationships between sFas-L or sFas and clinical
variables including the TNF-a system; levels of circulating
TNF-a and sTNF-Rs in COPD patients. Revealing the
answers to these questions may provide new insights into
the pathophysiology of patients with COPD.
Patients and methods
STUDY POPULATION
Thirty-four male patients with COPD were diagnosed
according to the criteria established by the American
Thoracic Society (27). Their irreversible chronic airflow
obstruction was confirmed by spirogram. The patients had
been clinically stable for at least 3 months and lacked
clinical signs of exacerbation. All patients had no clinical or
laboratory evidence of neoplasm, autoimmune, or infec-
tious disease. Patients with abnormal liver or renal function
tests were not included in this study. C-reactive protein
levels in the present COPD patients were not increased. Ten
patients in this study were receiving supplementary oxygen.TABLE 1. The study population
COPD patients (n=34)
Age (years) 71?9 (7?4)
Height (m) 1?59 (0?05)
BW (kg) 45?7 (6?9)
% of Normal BW (%) 81?8 (11?3)
BMI (kgm72) 18?0 (2?5)
% fat (%) 16?5 (5?4)
FVC (% predicted) 64?1 (22?2)
FEV1/FVC (%) 50?7 (19?0)
Arterial PO2 (torr) 63?1 (10?6)
Arterial PCO2 (torr) 45?8 (8?5)
TNF-a (pgml71) 6?45 (1?90)
sTNF-R55 (ngml71) 1?10 (0?49)
sTNF-R75 (ngml71) 3?58 (1?28)
Values presented are mean (SD).
NS: Not significant.
*Mann–Whitney’s U-test.Use of this oxygen was discontinued approximately 1 h
before the study. All patients were ex-smokers.
Thirty-five age-matched healthy male volunteers were
studied as control subjects. These control subjects had no
medical illnesses, had normal physical examinations,
peripheral blood counts, blood chemistries, and showed
no symptoms or signs of infection at the time of study. All
control subjects were non-smokers.
All subjects gave their informed consent to participate in
this study.
PULMONARY FUNCTION TEST
FVC and FEV1?0 were measured with standard spirometric
techniques (CHESTAC-25 part II EX; Chest Corp., Tokyo,
Japan). The highest value from at least three spirometric
manoeuvres was used. Reference values were those
proposed by Quanjer et al. (28). Arterial blood gas was
analysed with the subject breathing room air in the sitting
position (280 Blood Gas System; Ciba Corning Diagnostics
Corp., Medfield, MA, U.S.A.).
DETERMINATIONS OF CIRCULATING sFas-
L, sFas, TNF-a AND sTNF-Rs LEVELS
Blood samples were collected from the cubital vein in
subjects after an overnight fast. Both serum and plasma
were separated from blood cells by centrifugation at 1000 g
for 5min. All samples were stored at7708C until analysed.
The circulating levels of sFas-L and sFas were measured
in duplicate with enzyme-linked immunosorbent assay
(ELISA) kits (Medical & Biological Laboratories CO.,
LTD, Nagoya, Japan) (29). In short, microtitre plates were
coated with monoclonal Ab specific for sFas-L andHealthy subjects (n=35) P-value*
68?6 (8?8) NS
1?63 (0?08) 50?01
60?8 (9?1) 50?0001
103?4 (10?2) 50?0001
22?7 (2?2) 50?0001
24?4 (4?6) 50?0001
102?6 (23?0) 50?0001
74?5 (9?1) 50?0001
84?6 (9?3) 50?0001
42?4 (3?3) NS
5?21 (1?40) 50?001
0?70 (0?26) 50?0001
2?28 (0?58) 50?0001
TABLE 2. The number of subjects with and without
detectable serum levels of soluble Fas ligand in both groups
Detectable* Non-detectable
COPD 5 29
Control 2 33
Fisher’s exact probability test: P=0?26.
*The limit of detectability is 0?1 ngml71 in serum.
FIG. 1. Plasma sFas levels in COPD patients and in
healthy controls. Plasma sFas levels were determined, as
described in ‘Patients and Methods’. A sFas level from
one COPD patient was excluded because of the
inappropriate sample preparation. NS: not significant.
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measured as well as standards (recombinant sFas-L and
sFas, respectively) were added to individual wells. After
several washes to remove unbound proteins, murine
monoclonal Abs specific for sFas-L and sFas were added
to the wells, respectively. These monoclonal Abs were
conjugated to peroxidase. After another set of washes,
substrate solutions (hydrogen peroxide and tetramethyl-
benzidine) were added to the wells and colour developed in
proportion to the amounts of sFas-L and sFas, respectively.
The reactions were stopped by adding 2N sulphuric acid.
The colour generated were determined with a spectro-
photometric microtitre plate reader (model 450; Bio-Rad,
Richmond, CA, U.S.A.), by measuring the optical density
at 450 nm. The concentrations of sFas-L and sFas were
calculated from dose response curves based on reference
standards. The lower limit of detections for sFas-L and
sFas were 0?1 ngml71 and 0?5 ngml71, respectively. There
were no cross-reactivities of sFas-L ELISA kit to recombi-
nant TNF-a (R&D Systems Inc., Minneapolis, MN,
U.S.A.), or sFas ELISA kit to recombinant sTNF-R55
and R75 (R&D Systems Inc., Minneapolis, MN, U.S.A.).
Serum TNF-a, plasma sTNF-R55 and sTNF-R75 con-
centrations were also measured in duplicate with ELISA
kits (Quantikine; R&D Systems Inc., Minneapolis, MN,
U.S.A., (25,26). The lower limit of detection for TNF-a
assay was less than 0?18 pgml71 (high sensitivity kit). The
lower limit of detections for sTNF-R55 and R75 assays
were less than 30 pgml71 and 10 pgml71, respectively.
These three measurements are specific to the particular
substance and there is no cross-reaction.
STATISTICAL ANALYSIS
Because the normality hypothesis was not always fulfilled
for most of the variables, statistical analysis was performed
with the Mann–Whitney’s U-test for non-parametric data
to analyse the differences between the two groups. The
relationships between continuous variables were evaluated
with Spearman’s rank correlation technique. Fisher’s exact
probability test was used for categorical variables. Results
were expressed as mean (SD). Significance was determined at
the 5% level. Statistical analysis was done with the Statview
Statistical Package (Statview, Inc., Berkeley, CA, U.S.A.).
Results
THE STUDY POPULATION
Clinical characteristics, serum TNF-a and plasma sTNF-Rs
levels of both the COPD patients and the healthy controls
are summarized in Table 1. The present COPD patients
were associated with airflow limitation, decreased arterial
blood O2 pressure (PaO2) and increased arterial blood CO2
pressure (PaCO2). These COPD patients had significantly
lower body weight (BW), body mass index (BMI) and
percent body fat (%fat) compared with the control subjects.
We found that serum TNF-a, plasma sTNF-R55 andsTNF-R75 concentrations in COPD patients were signifi-
cantly higher than those of the healthy controls.
CIRCULATING LEVELS OF sFas-L AND sFas
IN COPD PATIENTS
We measured the circulating levels of sFas-L and sFas in
both groups. Since the limit of detectability for sFas-L is
0?1 ngml71, we divided the subjects into two groups with,
and without, detectable serum level of sFas-L (Table 2).
There was no significant difference in the number of
subjects with detectable serum levels of sFas-L between
COPD patients and control subjects (Fisher’s exact
probability test; P=0?26). In addition, there were no
changes in clinical variables between the patients with and
without detectable serum sFas-L. Similar to sFas-L, plasma
FIG. 2. Plasma sFas and sTNF-R55 (a) or sTNF-R75 (b)
levels in COPD patients. Plasma sTNF-R55 or R75 levels
were determined, as described in ‘Patients and Methods’.
A sFas level from one COPD patient was excluded
because of the inappropriate sample preparation. These
positive correlations were not observed in healthy
controls.
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compared with the healthy controls [3?74 (0?63) vs. 3?67
(0?48) ng /ml; P=0?89, Fig. 1]. There were no significant
correlations between circulating sFas levels and clinical
variables in patients with COPD. Interestingly, strong
positive correlations were observed between the plasma
levels of sFas and sTNF-Rs [sTNF-R55; r=0?710;
P50?0001, Fig. 2(a); sTNF-R75; r=0?714; P50?0001,
Fig. 2(b)]. These significant correlations were not observed
in the healthy controls.
Discussion
In this study, we showed that the circulating levels of sFas-
L and sFas were not significantly increased in clinically
stable patients with COPD. In addition, the circulating
levels of sFas-L and sFas were not associated with any of
the clinical variables in these patients except for the fact
that there were strong positive correlations betweencirculating levels of sFas and sTNF-Rs, the latter have
been reported to increase in various cachexic conditions
including COPD (24–26,30). In fact, there were trends of
inverse relationships between %fat and sTNF-Rs in the
present COPD patients, although these trends did not reach
statistical significance (data not shown).
Fas and sFas expressions are regulated by numerous
kinds of stimulation including TNF-a system in humans
(1–3). In addition, the interaction between sFas and sFas-L
is unknown in both the physiological conditions and the
pathophysiological conditions. Even though levels of
sTNF-Rs are increased, and there are correlations between
levels of sFas and sTNF-Rs in COPD patients, they do not
necessarily indicate that levels of sFas is increased in COPD
patients.
The results of this study are different from those reported
by Yasuda et al., who previously indicated that circulating
sFas level was increased in association with the disease
progression in COPD patients (31). We speculate that these
conflicting results are due to differences in the patient
population employed in their study. A considerable number
of their COPD patients showed increased levels of C-
reactive protein, an indicator of inflammation, compared to
the control subjects. This may imply that secondary change
due to exacerbations of COPD, infection for example,
enhanced the productions of pro-inflammatory cytokines,
which are capable of activating the Fas–Fas ligand system
(1–3). In contrast, we confirmed that C-reactive protein
levels in our COPD patients were not increased, so that we
could exclude the effect of non-specific inflammation on the
Fas–Fas ligand system in patients with COPD.
Serum level of sFas-L is known to increase and reflect
disease activity in patients with large granular lymphocytic
(LGL) leukaemia and natural killer (NK) cell lymphoma
(32). Systemic tissue destruction accompanied in these
patients is attributed to the elevated levels of circulating
sFas-L, which is produced by these malignant cells, and
induces apoptosis in systemic range (32). Since there is no
evidence of massive tissue destruction from apoptosis in
COPD patients, our result that circulating sFas-L level is
not increased in clinically stable patients with COPD, may
be reasonable. In contrast, sFas is also known to increase
and reflect disease activity in patients with autoimmune
diseases, such as systemic lupus erythematosus (SLE), and
in patients with haematopoietic or non-haematopoietic
malignancy (6,33,34). In such conditions, elevated sFas
levels are considered to impair Fas-mediated apoptosis and
develop abnormal growth of autoreactive T cell or tumour
cell (1–3). Our result that circulating sFas level is not
increased, and is not associated with clinical variables in
clinically stable patients with COPD, may suggest that Fas–
Fas ligand system is not involved in the pathophysiology in
patients with COPD independently.
The cell surface molecules of lymphocyte, CD27, CD30,
CD40, the OX-40 antigen, both types of the TNF receptor,
the NGF receptor, and Fas are all members of the same
family (1–3). For most of these molecules, soluble forms
have been identified (1–3, 33–35). Soluble forms of CD27,
the NGF receptor, TNF-R55 or R75, and Fas were found
to retain ligand binding activity and were detectable in
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biological effects of TNF were inhibited by sTNF-Rs (35).
Although the physiological functions of these soluble
receptors are not completely clarified, it is conceivable that
they play a role in regulating functions of the immune
system (1–3,33–35). The strong positive relationships
between circulating levels of sFas and sTNF-Rs in the
present COPD patients may imply that three soluble
receptors are mobilized together from identical sources to
circulating blood in these patients, although the principal
mechanisms generating soluble forms between Fas and
TNF-Rs are different; alternative mRNA splicing event for
sFas and cleavage by proteolysis for sTNF-Rs (1–3,36,37).
We have reported similar correlations in patients with
congestive heart failure (29). However, the pathophysiolo-
gical implications of these relationships in COPD patients
remains to be elucidated.
In conclusion, we found that the circulating levels of
sFas-L and sFas were not significantly increased in patients
with COPD. In addition, the circulating levels of sFas-L
and sFas were not associated with any of the clinical
variables in these patients. These results may suggest that
the Fas–Fas ligand system in not involved in the
pathophysiology in patients with COPD. However, further
studies may be required to elucidate the pathophysiological
relevance of the Fas–Fas ligand system to the development
of COPD at local sites (i.e. destructive changes of alveoli
and/or bronchioles) since such local events may not be
reflected in circulating blood.
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